Casi pharmaceuticals announces restructuring of partnership with juventas cell therapy

Casi pharmaceuticals announces restructuring of partnership with juventas cell therapy ltd.casi pharmaceuticals inc - casi receives co-commercial rights to second pipeline product.casi pharmaceuticals inc - casi increases its equity position in juventas.casi pharmaceuticals inc - casi and juventas to co-commercialize and co-market cd19 car-t (cnct19) therapy.casi pharmaceuticals - effective as of sept 22, juventas and shareholders agreed to certain conditions in connection with juventas' series b financing.casi pharmaceuticals - supplementary agreement provides casi with co-commercial rights to a second pipeline product from juventas.casi pharmaceuticals inc - juventas will waive rmb 70 million milestone payment due from casi.casi pharmaceuticals inc - casi and juventas will share a percentage of total net profits.casi pharmaceuticals - casi wuxi bio will invest rmb 70 million in juventas' series a plus equity, resulting in equity ownership of approximately 19.65%.casi pharmaceuticals - wei-wu he and james huang did not participate in committee's deliberations or approval of deal.
CASI Ratings Summary
CASI Quant Ranking